These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36720391)

  • 41. Gamma sterilization of pharmaceuticals--a review of the irradiation of excipients, active pharmaceutical ingredients, and final drug product formulations.
    Hasanain F; Guenther K; Mullett WM; Craven E
    PDA J Pharm Sci Technol; 2014; 68(2):113-37. PubMed ID: 24668600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk assessment report of potential impurities in cetirizine dihydrochloride.
    Leistner A; Haerling S; Kreher JD; Becker I; Jung D; Holzgrabe U
    J Pharm Biomed Anal; 2020 Sep; 189():113425. PubMed ID: 32599488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Risk-Based Approach to Evaluate and Control Elemental Impurities in Therapeutic Proteins.
    Luo Y; Sekhar C; Lee H; Fujimori K; Ronk M; Semin D; Nashed-Samuel Y
    J Pharm Sci; 2020 Nov; 109(11):3378-3385. PubMed ID: 32745562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meeting Report: N-Nitrosamine Impurity Control Strategies in the Pharmaceutical and Biotechnology Industries.
    Roberts SW; Lennard A; Mohan G; Bernstein J; Cauchon NS; Cole S; Curristin N; Huynh-Ba K; Kolz CN; Murti C; Tang K
    AAPS J; 2021 Jul; 23(4):94. PubMed ID: 34258657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da.
    Bercu J; Dirat O; Dobo K; Jolly R; Kenyon M; Harvey J; Nudelman R; Smith G; Trejo-Martin A; Urquhart M
    Regul Toxicol Pharmacol; 2024 Dec; 154():105704. PubMed ID: 39326488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality of Active Pharmaceutical Ingredients Present on Algerian Soil: Control of Impurities of Ciprofloxacin, Metronidazole and Fluconazole.
    Matmour D; Achachi N; Toumi H
    Ann Pharm Fr; 2022 May; 80(3):261-272. PubMed ID: 34687670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Purification of pharmaceutical excipients with supercritical fluid extraction.
    Ashraf-Khorassani M; Taylor LT; Waterman KC; Narayan P; Brannegan DR; Reid GL
    Pharm Dev Technol; 2005; 10(4):507-16. PubMed ID: 16370180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The modern approaches to the determination of the content of elemental impurities in the pharmaceutical substances with the use of inductively-coupled plasma mass-spectrometry].
    Bol'shov MA; Seregina IF; Uspenskaya EV; Titorovich OV; Syroeshkin AV; Maksimova TV; Pletneva TV
    Sud Med Ekspert; 2015; 58(6):31-33. PubMed ID: 26856057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of Extractable Elements from Elastomers.
    Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
    PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation.
    Hao G; Hu R; Wang X; Gao P; Wang L; Jiang M; Xin L; Tan G; Zhao Y; Sun F; Chu D; Lv J; You J; Huang F; Song X
    J Pharm Biomed Anal; 2023 Jan; 222():115066. PubMed ID: 36191442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
    Golob N; Grahek R; Ross M; Roškar R
    Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
    Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a Sensitive Screening Method for Simultaneous Determination of Nine Genotoxic Nitrosamines in Active Pharmaceutical Ingredients by GC-MS.
    Witkowska AB; Giebułtowicz J; Dąbrowska M; Stolarczyk EU
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can Pharmaceutical Excipients Threaten the Aquatic Environment? A Risk Assessment Based on the Microtox
    Turek M; Różycka-Sokołowska E; Koprowski M; Marciniak B; Bałczewski P
    Molecules; 2023 Sep; 28(18):. PubMed ID: 37764366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and validation of an ICP-MS method for the determination of elemental impurities in TP-6076 active pharmaceutical ingredient (API) according to USP 〈232〉/〈233〉.
    Chahrour O; Malone J; Collins M; Salmon V; Greenan C; Bombardier A; Ma Z; Dunwoody N
    J Pharm Biomed Anal; 2017 Oct; 145():84-90. PubMed ID: 28654780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of the use of axial viewed inductively coupled plasma atomic emission spectrometry with ultrasonic nebulization for the determination of select elemental impurities in oral drug products.
    Menoutis J; Parisi A; Verma N
    J Pharm Biomed Anal; 2018 Apr; 152():12-16. PubMed ID: 29414002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elemental impurities in pharmaceutical products adding fuel to the fire.
    Maithani M; Raturi R; Sharma P; Gupta V; Bansal P
    Regul Toxicol Pharmacol; 2019 Nov; 108():104435. PubMed ID: 31376414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies.
    Barber C; Antonucci V; Baumann JC; Brown R; Covey-Crump E; Elder D; Elliott E; Fennell JW; Gallou F; Ide ND; Jordine G; Kallemeyn JM; Lauwers D; Looker AR; Lovelle LE; McLaughlin M; Molzahn R; Ott M; Schils D; Oestrich RS; Stevenson N; Talavera P; Teasdale A; Urquhart MW; Varie DL; Welch D
    Regul Toxicol Pharmacol; 2017 Nov; 90():22-28. PubMed ID: 28822875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.